S. Clawson

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

D. Isenberg, C. Doré, M. Khamashta, 2016, The Lancet. Haematology.

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

D. Isenberg, C. Doré, M. Khamashta, 2015, Lupus.

A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.

M. Parmar, K. Grigor, R. Kockelbergh, 2007, The Journal of urology.

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

S. Barrans, J. Radford, W. Qian, 2008, Blood.

Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapuetic regimens : Results from the international Burkitt lymphoma collaborative group

A. LaCasce, J. Friedberg, R. Fisher, 2005 .

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

K. Maclennan, M. Sydes, J. Radford, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On Behalf of the Raps Trial Protocol Collaborators

D. Isenberg, C. Doré, M. Khamashta, 2022 .

Randomised comparison of ABVD with two multi-drug regimens (MDRs) in the treatment of advanced Hodgkin lymphoma (HL): Initial results of the UKLG LY09 study (ISRCTN 97144519).

Sydes, J. Radford, Paul D. Smith, 2003 .

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

D. Isenberg, C. Doré, M. Khamashta, 2016, The Lancet. Haematology.